top of page
  • Recruiting

NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Updated: May 25, 2022

Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06

NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma


emb-06

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma


The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-06 will also be assessed.


Sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd


Locations

Australia

China

 

ClinicalTrials.gov Identifier: NCT04735575